Possibly through CD8+ T-cell recruitment and improved natural killer cell-mediated ADCC efficiency, cetuximab alters the tumor microenvironment, thereby mediating conversion from rHGP to dHGP. The gene discussed is CD8A; the disease is neoplasm.